Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 1.00 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 3/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | WEE1 | P30291 | 2/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557026 | 1.00 | ABL1 (1.00) | ABL1MAP3K5SRCPDGFRBPDGFRA | |
| SCHEMBL23879895 | 0.93 | ABL1 (0.89) | ABL1MAP3K5SRCPDGFRBPDGFRA | |
| SCHEMBL29557024 | 0.89 | ABL1 (1.00) | ABL1MAP3K5SRCPDGFRBPDGFRA | |
| SCHEMBL23877670 | 0.89 | ABL1 (1.00) | ABL1MAP3K5SRCPDGFRBPDGFRA | |
| SCHEMBL23877687 | 0.85 | ABL1 (1.00) | ABL1MAP3K5SRCPDGFRBPDGFRA | |
| SCHEMBL23879900 | 0.79 | ABL1 (0.89) | ABL1SRCPDGFRBPDGFRAMAPK14 | |
| SCHEMBL2919202 | 0.76 | MAP3K5 (0.70) | ABL1MAP3K5SRCPDGFRBPDGFRA | |
| SCHEMBL29557319 | 0.74 | ABL1 (1.00) | ABL1SRCPDGFRBPDGFRAMAPK14 | |
| SCHEMBL29557265 | 0.74 | ABL1 (0.78) | ABL1SRCPDGFRBPDGFRAMAPK14 | |
| SCHEMBL29557191 | 0.74 | ABL1 (0.73) | ABL1SRCPDGFRBPDGFRAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136333-B2 | Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136333-B2 | Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136333-B2 | Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use | MAP3K7, MAP4K2, MAP3K8 | ABL1 145/4885MAP3K5 11/4885SRC 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.